Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials

IF 1.5 4区 医学 Q4 IMMUNOLOGY Central European Journal of Immunology Pub Date : 2024-01-09 DOI:10.5114/ceji.2023.134257
Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou
{"title":"Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials","authors":"Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou","doi":"10.5114/ceji.2023.134257","DOIUrl":null,"url":null,"abstract":"<b>Introduction:</b><br/>A growing number of randomized controlled trials (RCTs) have demonstrated the effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors in treating Crohn’s disease (CD). This study evaluated the efficacy of IL-23 and IL-12/23 inhibitors in the induction phase for the treatment of CD.<br/><br/><b>Material and methods:</b><br/>We searched the following databases from inception until December, 2022: Medline, Embase, Web of Science and the Cochrane Library. The primary outcome was the proportion of CD patients who achieved clinical remission at the end of the induction therapy period. Secondary outcomes included clinical response, endoscopic remission, endoscopic response and normalized C-reactive protein (CRP).<br/><br/><b>Results:</b><br/>After screening, 7 RCTs were included in our study. The meta-analysis showed that, in the induction period, more patients treated with IL-23 inhibitors and IL-12/23 inhibitors achieved clinical remission than patients with placebo therapy (RR = 2.11, 95% CI: 1.83-2.44; RR = 1.94, 95% CI: 1.64-2.29; respectively). The IL-23 inhibitor group and the IL-12/23 inhibitor group showed higher clinical response rates than the placebo group (RR = 1.92, 95% CI: 1.74-2,11; RR = 1.83, 95% CI: 1.61-2.09; respectively). In addition, the IL-23 inhibitor group had a higher endoscopic remission rate and endoscopic response rate than the placebo group; the corresponding pooled RRs were 3.40 (95% CI:2.57-4.50) and 2.65 (95% CI: 2.65-3.12), respectively.<br/><br/><b>Conclusions:</b><br/>IL-23 and IL-12/23 inhibitors were efficient methods in the induction treatment of CD.<br/><br/>","PeriodicalId":9694,"journal":{"name":"Central European Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ceji.2023.134257","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction:
A growing number of randomized controlled trials (RCTs) have demonstrated the effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors in treating Crohn’s disease (CD). This study evaluated the efficacy of IL-23 and IL-12/23 inhibitors in the induction phase for the treatment of CD.

Material and methods:
We searched the following databases from inception until December, 2022: Medline, Embase, Web of Science and the Cochrane Library. The primary outcome was the proportion of CD patients who achieved clinical remission at the end of the induction therapy period. Secondary outcomes included clinical response, endoscopic remission, endoscopic response and normalized C-reactive protein (CRP).

Results:
After screening, 7 RCTs were included in our study. The meta-analysis showed that, in the induction period, more patients treated with IL-23 inhibitors and IL-12/23 inhibitors achieved clinical remission than patients with placebo therapy (RR = 2.11, 95% CI: 1.83-2.44; RR = 1.94, 95% CI: 1.64-2.29; respectively). The IL-23 inhibitor group and the IL-12/23 inhibitor group showed higher clinical response rates than the placebo group (RR = 1.92, 95% CI: 1.74-2,11; RR = 1.83, 95% CI: 1.61-2.09; respectively). In addition, the IL-23 inhibitor group had a higher endoscopic remission rate and endoscopic response rate than the placebo group; the corresponding pooled RRs were 3.40 (95% CI:2.57-4.50) and 2.65 (95% CI: 2.65-3.12), respectively.

Conclusions:
IL-23 and IL-12/23 inhibitors were efficient methods in the induction treatment of CD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IL-23抑制剂和IL-12/23抑制剂在克罗恩病诱导治疗中的疗效:基于随机对照试验的荟萃分析
简介:越来越多的随机对照试验(RCT)证明了白细胞介素(IL)-23和IL-12/23抑制剂治疗克罗恩病(CD)的有效性。本研究评估了IL-23和IL-12/23抑制剂在诱导期治疗CD的疗效。材料与方法:我们检索了从开始到2022年12月的以下数据库:Medline、Embase、Web of Science和Cochrane图书馆。主要结果是在诱导治疗期结束时达到临床缓解的 CD 患者比例。次要结果包括临床反应、内镜缓解、内镜反应和正常化C反应蛋白(CRP)。荟萃分析表明,在诱导期,接受IL-23抑制剂和IL-12/23抑制剂治疗的患者比接受安慰剂治疗的患者获得临床缓解的比例更高(RR=2.11,95% CI:1.83-2.44;RR=1.94,95% CI:1.64-2.29;分别为)。IL-23抑制剂组和IL-12/23抑制剂组的临床应答率高于安慰剂组(RR = 1.92,95% CI:1.74-2,11;RR = 1.83,95% CI:1.61-2.09;分别为1.61-2.09)。结论:IL-23和IL-12/23抑制剂是诱导治疗CD的有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
17
审稿时长
6-12 weeks
期刊介绍: Central European Journal of Immunology is a English-language quarterly aimed mainly at immunologists.
期刊最新文献
Notch signaling pathway-based classification of bladder cancer in relation to tumor immune infiltration Interleukin-1 receptor-associated kinase 2 promotes inflammatory reactions by activating the nuclear factor kappa-B signaling pathway in diabetic nephropathy Influence of blood sample storage and different types of anticoagulants on results of NK cytotoxicity tests COVID-19 vaccination in healthcare workers: Long-term benefits and protection Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1